Press Releases April 8, 2026 08:00 PM

Certara to Report First Quarter 2026 Financial Results on May 11th, 2026

Certara Announces Q1 2026 Financial Results Release and Conference Call Date

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
CERT

Certara, Inc., a leader in model-informed drug development, will release its first quarter 2026 financial results on May 11th, 2026, prior to market open, followed by a management conference call. The company continues to serve a broad base of biopharmaceutical clients globally with its biosimulation technology and services.

Certara to Report First Quarter 2026 Financial Results on May 11th, 2026
CERT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Certara will report Q1 2026 financial results on May 11th, 2026, before market open.
  • A conference call to discuss the results will be held on the same day at 8:30 AM ET.
  • Certara provides biosimulation software and services to over 2,600 clients worldwide, impacting the biopharmaceutical sector.

RADNOR, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the first quarter of 2026 before market open on Monday, May 11th, 2026. Company management will host a conference call to discuss financial results at 8:30AM ET.

Investors interested in listening to the conference call are required to register online. It is recommended to register at least one day in advance.

A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/.

About Certara
Certara accelerates medicines using biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions, and regulatory agencies across 70 countries. Visit us at www.certara.com.  

Investor Relations Contact:
David Deuchler
Gilmartin Group
[email protected]

Media Contact:
Alyssa Horowitz
[email protected]


Risks

  • Financial results may not meet investor expectations leading to stock volatility.
  • Market conditions in the biopharmaceutical and technology sectors can impact future performance.
  • Regulatory changes in drug development processes may affect demand for Certara's services.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026